SG Americas Securities LLC Purchases 8,219 Shares of GRAIL, Inc. $GRAL

SG Americas Securities LLC boosted its position in shares of GRAIL, Inc. (NASDAQ:GRAL) by 304.3% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 10,920 shares of the company’s stock after acquiring an additional 8,219 shares during the quarter. SG Americas Securities LLC’s holdings in GRAIL were worth $646,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Wealth Enhancement Advisory Services LLC increased its position in shares of GRAIL by 21.4% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 34,195 shares of the company’s stock valued at $1,758,000 after purchasing an additional 6,032 shares during the last quarter. Caxton Associates LLP purchased a new stake in GRAIL during the second quarter valued at approximately $3,320,000. NWF Advisory Services Inc. bought a new position in GRAIL in the second quarter worth approximately $1,062,000. Legal Advantage Investments Inc. purchased a new position in shares of GRAIL during the 3rd quarter worth $1,242,000. Finally, Sheets Smith Investment Management purchased a new position in shares of GRAIL during the 3rd quarter worth $1,689,000.

GRAIL Stock Performance

Shares of GRAL stock opened at $116.06 on Friday. GRAIL, Inc. has a 52-week low of $20.44 and a 52-week high of $118.84. The firm has a market capitalization of $4.52 billion, a PE ratio of -9.98 and a beta of 4.52. The stock has a fifty day simple moving average of $96.07 and a two-hundred day simple moving average of $67.10.

GRAIL (NASDAQ:GRAL) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($2.46) EPS for the quarter, beating the consensus estimate of ($3.40) by $0.94. The business had revenue of $36.19 million for the quarter, compared to the consensus estimate of $33.83 million. GRAIL had a negative return on equity of 15.69% and a negative net margin of 286.43%. On average, sell-side analysts forecast that GRAIL, Inc. will post -15.15 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently commented on GRAL. Morgan Stanley upped their price objective on GRAIL from $85.00 to $110.00 and gave the stock an “equal weight” rating in a research note on Monday, December 1st. UBS Group set a $75.00 price target on GRAIL in a report on Friday, October 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a research report on Wednesday, October 8th. Canaccord Genuity Group lifted their price objective on GRAIL from $85.00 to $105.00 and gave the company a “buy” rating in a research report on Monday, November 17th. Finally, Guggenheim upgraded GRAIL from a “neutral” rating to a “buy” rating and set a $100.00 price objective for the company in a research note on Wednesday, November 12th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $97.50.

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.